BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38372808)

  • 1. VNP20009-Abvec-Igκ-MIIP suppresses ovarian cancer progression by modulating Ras/MEK/ERK signaling pathway.
    Wang Q; Tang Y; Dai A; Li T; Pei Y; Zhang Z; Hu X; Chen T; Chen Q
    Appl Microbiol Biotechnol; 2024 Feb; 108(1):218. PubMed ID: 38372808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy.
    Zhou DX; Wang XH; Xu X; Chen WJ; Wei J; Chen TT; Wei H
    Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated Salmonella engineered with an apoptosis-inducing factor (AIF) eukaryotic expressing system enhances its anti-tumor effect in melanoma in vitro and in vivo.
    Wang H; Chen T; Wan L; Lu J; Wei H; Deng KY; Wei J; Xin HB
    Appl Microbiol Biotechnol; 2020 Apr; 104(8):3517-3528. PubMed ID: 32095863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer.
    Wen J; Fu J; Ling Y; Zhang W
    Oncotarget; 2016 Feb; 7(8):9118-34. PubMed ID: 26824318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGF/EGFR Promotes Salivary Adenoid Cystic Carcinoma Cell Malignant Neural Invasion
    Ren Y; Hong Y; He W; Liu Y; Chen W; Wen S; Sun M
    Curr Cancer Drug Targets; 2022; 22(7):603-616. PubMed ID: 35410600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.
    Yan G; Ru Y; Yan F; Xiong X; Hu W; Pan T; Sun J; Zhang C; Wang Q; Li X
    Cell Commun Signal; 2019 May; 17(1):44. PubMed ID: 31092266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer.
    Kinross KM; Brown DV; Kleinschmidt M; Jackson S; Christensen J; Cullinane C; Hicks RJ; Johnstone RW; McArthur GA
    Mol Cancer Ther; 2011 Aug; 10(8):1440-9. PubMed ID: 21632463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
    Ogishima J; Taguchi A; Kawata A; Kawana K; Yoshida M; Yoshimatsu Y; Sato M; Nakamura H; Kawata Y; Nishijima A; Fujimoto A; Tomio K; Adachi K; Nagamatsu T; Oda K; Kiyono T; Osuga Y; Fujii T
    BMC Cancer; 2018 Dec; 18(1):1201. PubMed ID: 30509235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypo-glycosylated hFSH drives ovarian follicular development more efficiently than fully-glycosylated hFSH: enhanced transcription and PI3K and MAPK signaling.
    Hua G; George JW; Clark KL; Jonas KC; Johnson GP; Southekal S; Guda C; Hou X; Blum HR; Eudy J; Butnev VY; Brown AR; Katta S; May JV; Bousfield GR; Davis JS
    Hum Reprod; 2021 Jun; 36(7):1891-1906. PubMed ID: 34059912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of MIIP regulates human breast cancer proliferation, invasion and migration by mediated by IGFBP2.
    Du Y; Wang P
    Pathol Res Pract; 2019 Jul; 215(7):152440. PubMed ID: 31078343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Per2 overexpression on growth inhibition and metastasis, and on MTA1, nm23-H1 and the autophagy-associated PI3K/PKB signaling pathway in nude mice xenograft models of ovarian cancer.
    Wang Z; Li L; Wang Y
    Mol Med Rep; 2016 Jun; 13(6):4561-8. PubMed ID: 27082164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/ERK/STAT3 signaling.
    Ling L; Wen Y; Xiong Y; Liu X; Chen J; Liu T; Zhang B
    J Gene Med; 2024 Jan; 26(1):e3571. PubMed ID: 37483091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
    Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
    Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
    [No Abstract]   [Full Text] [Related]  

  • 18. CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway.
    Liu W; Wang L; Zhang J; Cheng K; Zheng W; Ma Z
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
    Chen C; Chang YC; Lan MS; Breslin M
    Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
    Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.